Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The most significant specialists visited by diagnosed GD patients by visit or by age were oncologists (both p < 0.001, Chi-square and T test) or ophthalmologists (p < 0.001, Chi-square; p < 0.01, T test).Clinical characteristics of the diagnosed GD and control cohortsFeaturesDiagnosed with GDControlsChi-squareT testN = 756N = 1,328,000N%Age at 1st event; years, mean (SD)N%Age at 1st event; years, mean (SD)Anemia Anemias61481.2243 (21)567,73942.7544 (22)******Blood disorder Coagulation defects314.149 (25)69220.5256 (20)*** Pancytopenia324.2344 (25)37940.2962 (18)*** Thrombocytopenia30045.7343 (22)26,6448.1257 (21)******Bone disorder Arthralgia192.5148 (18)12,9320.9756 (18)*** Arthrogryposis91.1968 (11)98820.7453 (19) Avascular necrosis314.148 (18)9260.0755 (18)*** Bone density disorders22930.2954 (17)49,0653.6967 (13)****** Bone pain658.643 (18)29580.2250 (21)*** Chondropathies101.3252 (24)89130.6748 (20)* Delayed skeletal maturation111.4648 (22)39080.2956 (20)*** Erlenmeyer flask deformity008270.0645 (20) Joint dislocation20.2658 (5)30130.2343 (21) Kyphosis151.9843 (29)37090.2862 (22)**** Osteoarthritis15019.8460 (15)112,9288.563 (14)****** Osteolysis50.6666 (7)2030.0258 (19)*** Osteonecrosis506.6147 (18)14640.1156 (17)*** Osteopenia7710.1948 (19)11,1400.8466 (12)*** Osteoporosis587.6758 (15)13,1190.9968 (13)*** Pathological fracture111.4653 (18)22830.1765 (19)*** Spine deformation001360.0440 (29)Cerebral/nervous system disorder Ataxia101.3251 (29)45340.3462 (19)*** Bradykinesia40.5362 (11)3590.0370 (13)*** Cranial nerve disorders10.13842670.0255 (20) Developmental regression516.7536 (29)34,4752.639 (31)***** Dysphagia577.5450 (27)34,1062.5758 (21)****** Extrapyramidal disorder50.6653 (15)16600.1352 (21)*** Gaze palsy10.1346770.0149 (27)* Hearing impairment668.7355 (23)57,5554.3353 (25)***** Hemiplegia/hemiparesis70.9355 (22)62150.4763 (19)* Hydrocephalus60.7960 (29)20780.1650 (28)*** Laryngeal spasm30.429 (41)4680.0440 (27)*** Muscle hypotonia70.933 (2)5870.049 (17)*** Myoclonic seizure10.13171440.0130 (19) Nerve root compression004190.0356 (17) Oculomotor apraxia40.5328 (36)2860.0239 (29)*** Opticokinetic nystagmus50.6626 (32)11260.0840 (26)*** Paralytic strabismus10.13156760.0528 (26) Parkinson222.9164 (11)34340.2673 (11)*** Tonic clonic seizure10.1591590.0542 (23)Development disorders Delayed puberty10.13132920.0216 (9) Growth retardation60.7915 (13)2190.0211 (14)***** Short stature70.9311 (4)19080.1411 (11)***Eye disorder Corneal disorders70.9349 (32)23960.1858 (20)*** Non diabetic retinopathy30.461 (26)22320.1750 (28)General signs Abdominal pain21728.747 (22)227,90817.1642 (22)****** Elevated CRP50.6652 (16)22040.1750 (21)** Fatigue22229.3747 (19)111,6058.451 (21)**** Fever14318.9241 (23)171,63412.9234 (25)****** Gingival bleeding20.2651 (32)2300.0242 (28)*** Muscle atrophy40.5377 (12)1200.0161 (16)*** Tremor274.1253 (22)41531.2756 (20)*** Vitamin D deficiency11617.6850 (19)20,3216.254 (18)****Heart disorder Valve calcification91.3772 (14)17400.5369 (14)**Hepatic disorders Cirrhosis141.8546 (16)58890.4460 (13)*** Hepatic fibrosis60.7948 (29)5140.0455 (15)*** Hepatitis192.5149 (23)47610.3654 (17)*** Portal hypertension131.7238 (22)27340.2159 (13)***Immunology Polyclonal gammopathy40.5360 (19)3080.0252 (22)***Kidney disorder Acute kidney disease314.166 (14)42140.3256 (20)*** Hematuria749.7953 (21)61,3494.6252 (21)**** Proteinuria344.553 (22)18,0601.3653 (21)***Malignancy Liver neoplasm30.455 (26)14520.1163 (14) Malignant melanoma50.6663 (7)30920.2362 (15)* Multiple myeloma70.9361 (10)12130.0967 (13)*** Non Hodgkin Lymphoma81.0661 (27)17380.1365 (16)*** Other malignant neoplasms20.2638 (46)1500.0156 (21)*** Pancreatic cancer20.2655 (15)13810.167 (13) Uncertain neoplasms416.2558 (16)12590.3860 (19)***Organomegaly Hepatomegaly13417.7235 (22)62300.4752 (18)***** Splenomegaly23836.2839 (21)20360.6252 (19)****** Ventriculomegaly20.374 (0)15058 (26)***Perinatal disorders Hydrops fetalis10.13234021 (15)*** Ichthyosis002210.0244 (27)Psychiatric disorders Dementia non-senile192.5169 (16)17,8881.3578 (10)***** Depression15921.0350 (20)165,33912.4546 (20)*****Respiratory disorder Interstitial pulmonary abnormality70.9344 (36)26000.267 (16)***** Pulmonary fibrosis131.7263 (20)68650.5267 (15)****** Pulmonary hypertension334.3758 (20)11,1730.8469 (17)*** Respiratory failure354.6357 (29)27,6762.0863 (20)*******p value < 0.05**p value < 0.01***p value < 0.001Visits to specialist by the diagnosed GD and control cohortsFeaturesDiagnosed with GD N = 756Controls N = 1,328,000Chi-squareT test (no. visit)T test (age)N%No. of visits (mean)Age at 1st event; years, mean (SD)N%No. of visits (mean)Age at 1st event; years, mean (SD)Gastroenterology709.261.450 (21)56,0984.221.6953 (18)***General Practice101.3219.1152 (21)13,8161.042.7141 (23)Hematology101.326.0556 (15)14550.112.754 (17)***Hepatology40.531.1842 (15)6430.052.5551 (17)***Internal Medicine19025.132.0351 (18)176,76213.313.4649 (20)***Neurology18624.63.5542 (21)64,2354.842.7145 (22)***Oncology13117.336.4243 (23)24,6441.864.1853 (21)*********Ophthalmology476.221.0910 (21)40,4093.041.8749 (23)*******Orthopedic Surgery10714.151.8149 (21)62,5274.712.6948 (21)***Pain Medicine101.320.4247 (23)58220.441.8153 (16)***Pediatrics688.994.9312 (16)90,2386.85.9710 (15)*Radiology11915.741.5448 (23)91,8926.921.5846 (21)***Rheumatology233.040.6660 (18)13,4021.012.1854 (17)****p value < 0.05**p value < 0.01***p value < 0.001

Source: Clinical characteristics and visits to specialists. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Development of a rare disease algorithm to identify persons at risk of Gaucher disease using electronic health records in the United States

Study design awaiting verification · Orphanet Journal of Rare Diseases · 2023

Original publication title

Development of a rare disease algorithm to identify persons at risk of Gaucher disease using electronic health records in the United States

Amanda Wilson; Alexandra Chiorean; Mario Aguiar; Davorka Sekulic; Patrick Pavlick; Neha Shah; Lisa Sniderman King; Marie Génin; Mélissa Rollot; Margot Blanchon; Simon Gosset; Martin Montmerle; Cliona Molony; Alexandra Dumitriu

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The age-based algorithm identified younger patients, while the prevalence-based identified patients with advanced clinical manifestations. Their combined use better captures GD heterogeneity. The two algorithms were about 10 to 20-fold more efficient at identifying GD patients than the clinical diagnostic algorithm. Application of these algorithms could shorten diagnostic delay by identifying undiagnosed GD patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Early diagnosis of Gaucher disease (GD) allows for disease-specific treatment before significant symptoms arise, preventing/delaying onset of complications. Yet, many endure years-long diagnostic odysseys. We report the development of a machine learning algorithm to identify patients with GD from electronic health records.

Source: Background

Abstract: What methods does the paper describe?

We utilized Optum’s de-identified Integrated Claims-Clinical dataset (2007 to 2019) for feature engineering and algorithm training/testing, based on clinical characteristics of GD. Two algorithms were selected: one based on age of feature occurrence (age-based), and one based on occurrence of features (prevalence-based). Performance was compared with an adaptation of the available clinical diagnostic algorithm for identifying patients with diagnosed GD. Undiagnosed patients highly-ranked by the algorithms were compared with diagnosed GD patients.

Source: Methods

Abstract: Results

Splenomegaly was the most important predictor for diagnosed GD with both algorithms, followed by geographical location (northeast USA), thrombocytopenia, osteonecrosis, bone density disorders, and bone pain. Overall, 1204 and 2862 patients, respectively, would need to be assessed with the age: and prevalence-based algorithms, compared with 20,743 with the clinical diagnostic algorithm, to identify 28 patients with diagnosed GD in the integrated dataset. Undiagnosed patients highly-ranked by the algorithms had similar clinical manifestations as diagnosed GD patients.

Source: Results

Abstract: Conclusions

The age-based algorithm identified younger patients, while the prevalence-based identified patients with advanced clinical manifestations. Their combined use better captures GD heterogeneity. The two algorithms were about 10 to 20-fold more efficient at identifying GD patients than the clinical diagnostic algorithm. Application of these algorithms could shorten diagnostic delay by identifying undiagnosed GD patients.

Source: Conclusions
Authors’ abstract

Background

Early diagnosis of Gaucher disease (GD) allows for disease-specific treatment before significant symptoms arise, preventing/delaying onset of complications. Yet, many endure years-long diagnostic odysseys. We report the development of a machine learning algorithm to identify patients with GD from electronic health records.

Methods

We utilized Optum’s de-identified Integrated Claims-Clinical dataset (2007 to 2019) for feature engineering and algorithm training/testing, based on clinical characteristics of GD. Two algorithms were selected: one based on age of feature occurrence (age-based), and one based on occurrence of features (prevalence-based). Performance was compared with an adaptation of the available clinical diagnostic algorithm for identifying patients with diagnosed GD. Undiagnosed patients highly-ranked by the algorithms were compared with diagnosed GD patients.

Results

Splenomegaly was the most important predictor for diagnosed GD with both algorithms, followed by geographical location (northeast USA), thrombocytopenia, osteonecrosis, bone density disorders, and bone pain. Overall, 1204 and 2862 patients, respectively, would need to be assessed with the age: and prevalence-based algorithms, compared with 20,743 with the clinical diagnostic algorithm, to identify 28 patients with diagnosed GD in the integrated dataset. Undiagnosed patients highly-ranked by the algorithms had similar clinical manifestations as diagnosed GD patients.

Conclusions

The age-based algorithm identified younger patients, while the prevalence-based identified patients with advanced clinical manifestations. Their combined use better captures GD heterogeneity. The two algorithms were about 10 to 20-fold more efficient at identifying GD patients than the clinical diagnostic algorithm. Application of these algorithms could shorten diagnostic delay by identifying undiagnosed GD patients.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13023-023-02868-2.

Publication and source details

Original title: Development of a rare disease algorithm to identify persons at risk of Gaucher disease using electronic health records in the United States

Amanda Wilson; Alexandra Chiorean; Mario Aguiar; Davorka Sekulic; Patrick Pavlick; Neha Shah; Lisa Sniderman King; Marie Génin; Mélissa Rollot; Margot Blanchon; Simon Gosset; Martin Montmerle; Cliona Molony; Alexandra Dumitriu

Orphanet Journal of Rare Diseases · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/100004339Sanofi

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:30:02.889226+00:00

DOI: 10.1186/s13023-023-02868-2 · PMC10492341